Compare vaccination rates across Washington state agencies with our updating tracker
seattletimes.com/seattle-news/compare-vaccination-rates-across-washington-state-agencies-with-our-updating-tracker/
Story Details
| Last Updated | Oct 22 21 |
| Total Articles | 4 |
News on this topic
The case against Cuomo weakens: Because Donald Trump was no longer in office, Majority Leader Mitch McConnell persuaded his Republican conference in the Senate ...
nydailynews.com/opinion/ny-oped-the-case-against-cuomo-teeters-20211022-ykgbhekj35d2nezanwzy3gmnqm-story.html
Adolescents: Comirnaty lowers infection and disease risk significantly: The largest analysis to date of real-world data from young people from Israel shows: The ...
pharmazeutische-zeitung.de/comirnaty-senkt-infektions-und-krankheitsrisiko-deutlich-128752/
Phase III data: Booster vaccination with Comirnaty highly effective: The companies Biontech and Pfizer announce the first results of a phase III study on ...
pharmazeutische-zeitung.de/auffrischimpfung-mit-comirnaty-hochwirksam-128761/
More articles on this subject
Previous
The case against Cuomo weakens: Because Donald Trump was no longer in office, Majority Leader Mitch McConnell persuaded his Republican conference in the Senate ...
nydailynews.com/opinion/ny-oped-the-case-against-cuomo-teeters-20211022-ykgbhekj35d2nezanwzy3gmnqm-story.html
Adolescents: Comirnaty lowers infection and disease risk significantly: The largest analysis to date of real-world data from young people from Israel shows: The ...
pharmazeutische-zeitung.de/comirnaty-senkt-infektions-und-krankheitsrisiko-deutlich-128752/
Phase III data: Booster vaccination with Comirnaty highly effective: The companies Biontech and Pfizer announce the first results of a phase III study on ...
pharmazeutische-zeitung.de/auffrischimpfung-mit-comirnaty-hochwirksam-128761/
US FDA approves Pfizer's gene therapy for rare bleeding disorder: The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday ...
reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-pfizers-gene-therapy-rare-bleeding-disorder-2024-04-26/
Quick Glance: FDA approves Pfizer’s gene therapy for hemophilia B
- The FDA has approved Pfizer's first gene therapy drug for a rare inherited bleeding disorder.
- Beqvez, a unique gene therapy drug by Pfizer, has been approved for adults with moderate to severe hemophilia B.
- The drug enables patients to produce Factor IX themselves to prevent and control bleeding.
- Pfizer is competing with a similar treatment from CSL Behring and planning more gene therapies for various genetic disorders.
Pfizer vs Moderna battle over COVID vaccine patents begins in UK: Pfizer and BioNTech asked a London court to revoke rival Moderna's patents over technology key ...
reuters.com/business/healthcare-pharmaceuticals/pfizer-vs-moderna-battle-over-covid-vaccine-patents-begins-uk-2024-04-23/
Dividend Harvesting Portfolio Week 164: $16,400 Allocated, $1,466.94 In Projected Dividends
seekingalpha.com/article/4685001-dividend-harvesting-portfolio-week-164-16400-allocated-1466-94-in-projected-dividends
Paid articlePaid
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology: GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday ...
reuters.com/business/healthcare-pharmaceuticals/glaxosmithkline-sues-pfizer-biontech-over-covid-19-vaccine-technology-2024-04-25/
Almost as much cash as market capitalization: Biontech plans cancer drug development with 17.5 billion euros cash from vaccine sales.
boerse-online.de/nachrichten/geld-und-vorsorge/fast-so-viel-cash-wie-boersenwert-20355923.html
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.: Pfizer’s patent expirations are great for humanity but terrible for investors ...
barrons.com/articles/big-pharma-stocks-investors-mistakes-90e3c575
Paid articlePaid
Mainz after the boom: Too many expenses and projects?: For two years, income in Mainz was bubbling. Now they are declining more than forecast ...
allgemeine-zeitung.de/lokales/mainz/stadt-mainz/mainz-nach-dem-boom-zu-viele-ausgaben-und-projekte-3405908
Ad group WPP trails rivals with decline in organic revenue: Britain's WPP became a clear laggard among global ad companies with a drop in organic revenue drop in ...
reuters.com/business/media-telecom/ad-group-wpp-reports-16-drop-first-quarter-organic-growth-2024-04-25/
Vaccine: Biontech fuels hope in the fight against pancreatic cancer: The Mainz-based mRNA pioneer is working flat out on innovative therapies against cancer ...
faz.net/aktuell/wirtschaft/unternehmen/biontech-naehrt-hoffnung-im-kampf-gegen-bauchspeicheldruesenkrebs-19637578.html
Quick Glance: Vaccine: Biontech's Hopeful Fight Against Pancreatic Cancer
- Mainz-based mRNA pioneer works on innovative cancer treatments.
- New study data show potential for personalized cancer vaccines.
- Autogene Cevumeran triggers immune response in pancreatic cancer patients.
- Biontech aims to improve treatment standards in oncology with mRNA-based vaccines.
Pancreatic cancer: Biontech reports initial successes with “vaccination”: Activated “killer cells” are intended to destroy tumor foci and prevent relapse
nachrichten.at/meine-welt/gesundheit/biontech-meldet-erste-erfolge-bei-impfung-gegen-pankreaskrebs;art114,3938755
Quick Glance: Hopeful Results in Pancreatic Cancer Treatment
- Pancreatic cancer is among the most common cancers in Austria.
- Biontech reports success with new vaccine BNT122 against the cancer.
- Vaccine activates "killer cells" and prevents relapses.
- Surgical removal and chemotherapy improve survival chances.
Pfizer RSV shot meets goals in trial of high-risk adults under age 60: Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well ...
reuters.com/business/healthcare-pharmaceuticals/pfizer-rsv-shot-meets-goals-trial-high-risk-adults-under-age-60-2024-04-09/
The Best Defensive Stocks to Buy: These 10 defensive stocks supply investors with reliable earnings, and often dividends, when markets look uncertain.
morningstar.com/stocks/best-defensive-stocks-buy
Vaccine: Biontech fuels hope in the fight against pancreatic cancer: The Mainz-based mRNA pioneer is working flat out on innovative therapies against cancer ...
faz.net/aktuell/wirtschaft/unternehmen/biontech-naehrt-hoffnung-im-kampf-gegen-bauchspeicheldruesenkrebs-19637578.html
Quick Glance: Innovative Cancer Therapy: Biontech's Advancement
- Biontech is actively developing over twenty cancer medications with promising results.
- Current developments and potential market introductions of cancer treatments.
- Significance of Biontech's promising results against pancreatic cancer.
Better than BioNTech or Moderna? This share has been beating the market for years - can it do it again?
boerse-online.de/nachrichten/aktien/besser-als-biontech-oder-moderna-diese-aktie-schlaegt-den-markt-seit-jahren-kann-sie-das-wieder-20355498.html
Breakthrough in cancer treatment? New data makes doctors euphoric: Could cancer soon be curable? A certain vaccine is showing initial positive effects in ...
infranken.de/ratgeber/gesundheit/durchbruch-in-der-krebsbehandlung-neue-daten-machen-mediziner-euphorisch-art-5855650
Pfizer wins pause on Moderna's COVID-19 patent lawsuit: Moderna's patent lawsuit claiming Pfizer and BioNTech copied its COVID-19 vaccine technology will be put ...
reuters.com/legal/litigation/pfizer-wins-pause-modernas-covid-19-patent-lawsuit-2024-04-12/
"Misleading claims": The UK audit authority criticizes the pharmaceutical company Pfizer. The vaccine against Covid-19 was illegally advertised on social media ...
weltwoche.ch/daily/irrefuehrende-behauptungen-die-britische-pruefbehoerde-kritisiert-den-pharmakonzern-pfizer-in-den-sozialen-medien-sei-illegal-fuer-den-impfstoff-gegen-covid-19-geworben-worden/
Red numbers after the boom: This is what Mainz's finances look like: After the Biontech boom, the Mainz budget slipped significantly into the red for the second ...
allgemeine-zeitung.de/lokales/mainz/stadt-mainz/rote-zahlen-nach-dem-boom-so-sehen-die-mainzer-finanzen-aus-3492267
Eli Lilly: billions invested in the pharmaceutical industry: Eli Lilly and other pharmaceutical companies are investing a lot of money in Germany. Why ...
sueddeutsche.de/wirtschaft/medikamente-eli-lilly-wacker-chemie-biontech-investitionen-vfa-deindustrialisierung-1.6531745
Paid articlePaid Goldman Sachs: The Best Dividend Growth Stocks for Investors to Watch Now: Goldman Sachs recommends high-dividend stocks for 2024 with over 6% growth.
boerse-online.de/nachrichten/aktien/goldman-sachs-die-besten-dividendenwachstumsaktien-die-fuer-anleger-jetzt-interessant-sind-20355982.html
Drugmakers' low U.S. taxes belie their high sales: Most of the largest pharmaceutical companies report losing money in the United States ...
npr.org/sections/health-shots/2024/04/15/1244876740/drugmakers-low-taxes-us
Were COVID-19 Vaccines to Blame for Infertility? Heart Attacks? A New Report Weighs In
usnews.com/news/health-news/articles/2024-04-16/were-covid-19-vaccines-to-blame-for-infertility-heart-attacks-a-new-report-weighs-in
Medicine and research: Why so many companies are investing in RNA technology: The three letters RNA represent a revolution in medicine. Companies from the ...
faz.net/aktuell/rhein-main/warum-so-viele-unternehmen-in-rna-investieren-19625909.html
Paid articlePaid Now the EU public prosecutor's office is also investigating von der Leyen - and the German media is still silent - The World Week
weltwoche.de/daily/nun-ermittelt-auch-die-eu-staatsanwaltschaft-gegen-von-der-leyen-und-die-deutschen-medien-schweigen-noch-immer/
Big Pharma Stocks Need a Rethink. Investors Keep Making the Same Mistake.: Pfizer’s patent expirations are great for humanity but terrible for investors ...
barrons.com/articles/big-pharma-stocks-investors-mistakes-90e3c575
Paid articlePaid
The 2024 Forbes Entrepreneurial CMO 50 List: By The Numbers: The data and details behind the CMOs and marketers making the 2024 Forbes Entrepreneurial CMO 50 ...
forbes.com/sites/sethmatlins/2024/04/15/the-2024-forbes-entrepreneurial-cmo-50-list-by-the-numbers/
Pfizer RSV Vaccine Could Get Wider Use. New Study Suggests a Benefit For All Adults.
barrons.com/articles/pfizer-fda-rsv-vaccine-shot-gsk-moderna-4b1d50cc
Paid articlePaid
Activist investor blasts Novavax for not using mRNA fears to boost COVID-19 vaccine sales
qz.com/novavax-covid19-mrna-1851410267
Quick Glance: Criticism of Novavax for Missed Opportunities in Boosting COVID-19 Vaccine Sales
- Shah Capital called for immediate changes in the company's board.
- The activist hedge fund Shah Capital criticized Novavax's leadership for not capitalizing on concerns some individuals have about mRNA vaccines to increase sales of its traditional, protein-based COVID-19 vaccine.
- Findings from a survey of 1,500 Americans by the Annenberg Public Policy Center (APPC) at the University of Pennsylvania revealed an increase in the spread of vaccine misinformation.
- The limited use of COVID-19 vaccines is also affecting other vaccine manufacturers. In the U.S., only 14% of adults have received an updated COVID-19 vaccine for 2023-2024, according to the Centers for Disease Control and Prevention.
Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round up
qz.com/moderna-cancer-vax-astrazeneca-ceo-pay-drug-shortages-1851404812
Morgan Stanley bullish on biotech: That's why Pfizer and Co's shares could soon take off
boerse-online.de/nachrichten/aktien/morgan-stanley-bei-biotech-bullisch-darum-koennten-die-aktien-von-pfizer-und-co-bald-richtig-abgehen-20354537.html
Pneumococcal vaccine: Apexxnar® becomes Prevenar 20®: The pneumococcal vaccine Apexxnar® is no longer only approved for adults aged 18 and over ...
ptaheute.de/aktuelles/2022/04/27/neuer-pneumokokken-impfstoff-fuer-erwachsene
After Boehringer and Lilly, the Chancellor is now also visiting Merck: First Biontech, then Boehringer, Lilly in Alzey, now Merck in Darmstadt and the BKA in ...
allgemeine-zeitung.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/nach-boehringer-und-lilly-besucht-der-kanzler-nun-auch-merck-3514944
Pfizer Receives FDA Approval for Bleeding Disorder Treatment: The treatment, Beqvez, is for adults with moderate to severe hemophilia B.
barrons.com/articles/pfizer-fda-bleeding-disorder-stock-price-dca9b947
Paid articlePaid
Quarterly figures: Pfizer loss pushes WPP's balance sheet down: The advertising holding WPP has presented its business figures for the first quarter of 2024 ...
horizont.net/agenturen/nachrichten/quartalszahlen-pfizer-verlust-drueckt-die-bilanz-von-wpp-nach-unten-219520
Paid articlePaid Unveiling Pfizer's Potent Cocktail: Key Drivers Of Free Cash Flow Growth: Pfizer announced positive results from a pivotal clinical trial evaluating Abrysvo's ...
seekingalpha.com/article/4684677-pfizer-stock-key-drivers-of-free-cash-flow-growth
Paid articlePaid Goldman Sachs: The experts are now betting on these new growth stocks: New high ROE growth stocks added by Goldman Sachs, including Amazon, Uber and Pfizer.
boerse-online.de/nachrichten/aktien/goldman-sachs-auf-diese-neuen-wachstumsaktien-setzen-die-experten-jetzt-20355554.html
Eli Lilly, Biontech and Co: Where the country should make improvements: Are science and the economy in Rhineland-Palatinate doing well or badly? The members of ...
allgemeine-zeitung.de/politik/politik-rheinland-pfalz/eli-lilly-biontech-und-co-wo-das-land-nachbessern-soll-3491494
Doubts about the Greek economic miracle: Greece is suffering from Europe's slump and needs further structural reforms. That is the tenor of the annual Delphi ...
faz.net/aktuell/wirtschaft/zweifel-am-griechischen-wirtschaftswunder-19651596.html
Paid articlePaid Pfizer's Doldrums, Just A Bad Case Of COVID-19?: Pfizer may be worth buying as the COVID-based product revenues decline and equilibrate ...
seekingalpha.com/article/4683994-pfizer-doldrums-just-a-bad-case-of-covid-19-pfe-stock
Paid articlePaid Moderna's new cancer vax, AstraZeneca CEO's big pay, and record-high drug shortages: Pharma news round up
qz.com/moderna-cancer-vax-astrazeneca-ceo-pay-drug-shortages-1851404812
Stock exchange: It takes more than just TUI: TUI returns to the German stock exchange. But that alone hardly helps the capital market in this country.
faz.net/aktuell/wirtschaft/es-braucht-mehr-als-nur-tui-19639524.html
5 Top Dividend Stocks to Buy From the Best Managers: These cheap dividend stocks are popular among highly rated concentrated fund managers.
morningstar.com/stocks/5-top-dividend-stocks-buy-best-managers
Vaccine deal with Pfizer: Ursula von der Leyen in the sights of corruption hunters
rundschau-online.de/red/impfstoff-deal-mit-pfizer-von-der-leyen-im-visier-der-korruptionsjaeger-770493
Stefan Homburg: CDU Council invites Schwurbel professor to give a lecture: The CDU Economic Council invites you to a lecture with a professor who is notorious ...
t-online.de/nachrichten/deutschland/gesellschaft/id_100378778/stefan-homburg-cdu-rat-laedt-schwurbel-professor-zum-vortrag.html
Quick Glance: Stefan Homburg: Controversy Surrounding Lecture at Business Council
- The CDU's Business Council invites controversial Professor Stefan Homburg, known for spreading misinformation about Corona.
- Homburg, once a respected expert, faced criticism due to questionable statements during the pandemic.
- The decision to invite Homburg sparks outrage and criticism for his controversial views, especially upsetting cancer patients.
- The Business Council, a lobbying organization with ties to the CDU, faces scrutiny for organizing influential supporters and attracting backlash over the invitation.
Biontech is probably in the red this year: Biontech could end a financial year with losses in 2024 for the first time since the pandemic ...
wiesbadener-kurier.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/biontech-schreibt-dieses-jahr-wohl-rote-zahlen-3464126
Quick Glance: Biontech: Financial Situation and Product Portfolio
- Biontech is expected to slip into the red this year. Indications suggest that losses will be incurred.
- Biontech launched an immunization campaign half a year ago in Mainz with posters encouraging medical consultation.
- The company holds product aces, including vaccines and treatments combating diseases.
- The financial status reflects predicted losses despite an array of promising products.
Things are getting tight for Ursula von der Leyen: criminal investigators are looking into the Pfizer deal
berliner-zeitung.de/wirtschaft-verantwortung/es-wird-eng-fuer-ursula-von-der-leyen-strafermittler-untersuchen-pfizer-deal-li.2201815
European prosecutors target von der Leyen over vaccine deals: The European Public Prosecutor’s Office has become involved in the “Pfizergate” scandal involving ...
focus.de/politik/pfizergate-europaeische-staatsanwaelte-nehmen-von-der-leyen-wegen-impfstoff-deals-ins-visier_id_259817356.html
Investigation against von der Leyen over Pfizer deal: In 2021, the Commission President and Pfizer CEO Albert Bourla agreed a vaccine deal worth billions ...
nzz.ch/international/umstrittener-impfstoff-deal-nun-ermitteln-europas-korruptionsjaeger-gegen-ursula-von-der-leyen-ld.1824589
Paid articlePaid
Astra, Pfizer Boost China Bets Despite US Drive to Decouple: The chief executive officers of AstraZeneca Plc and Pfizer Inc. pledged to support expansion of ...
bloomberg.com/news/articles/2024-03-26/astra-pfizer-double-down-on-china-investment-amid-us-tensions
Paid articlePaid Conservative groups object to 'naming names' rule from Pfizer diversity decision: Six right-leaning nonprofits have called on a U.S. appeals court to reconsider ...
reuters.com/legal/government/column-conservative-groups-object-naming-names-rule-pfizer-diversity-decision-2024-04-01/
Biontech: Bringing the first cancer drug onto the market in 2026: The Mainz company Biontech is known for its Covid-19 vaccine - and rich - become ...
op-marburg.de/gesundheit/biontech-erstes-krebs-medikament-2026-auf-den-markt-bringen-KIDG6SA66BLXRM2UL6P2I6UBSY.html
Quick Glance: BioNTech Focuses on Cancer Drug Development after Revenue Plunge
- BioNTech reported a significant drop in revenue and earnings in 2023 as it shifts focus towards cancer drug development.
- The company aims for revenues between 2.5 billion to 3.1 billion euros in 2024.
- BioNTech plans to launch its first oncology drug in 2026 and secure ten indication approvals by 2030.
- Partner Pfizer anticipates a decline in sales for the COVID-19 vaccine, while BioNTech invests in scaling up its oncology business.
Morningstar reveals: These 10 moat stocks are the most undervalued: This list of 10 stocks has it all. According to the US experts at Morningstar ...
boerse-online.de/nachrichten/aktien/morningstar-gibt-preis-diese-10-burggraben-aktien-sind-am-staerksten-unterbewertet-20354078.html
Biontech's business collapses massively: buy shares cheaply now?: Corona is over, and the numbers and share price at vaccine manufacturer Biontech are collapsing ...
capital.de/geld-versicherungen/biontechs-geschaeft-bricht-massiv-ein--aktie-jetzt-guenstig-kaufen--34561014.html
Paid articlePaidQuick Glance: Biontech: Massive Business Decline Post-COVID
- As COVID ends, Biontech faces declining numbers and stock prices.
- A study reveals the significant impact of COVID on life expectancy.
- Biontech gained global recognition with the mRNA vaccine.
- The company is now focusing on new treatments for cancer to bounce back.
Does she know more? Star investor Cathie Wood has just signed up for this BioNTech competitor
boerse-online.de/nachrichten/aktien/weiss-sie-mehr-bei-diesem-biontech-konkurrent-hat-cathie-wood-gerade-zugeschlagen-20353621.html
BioNTech gets US agency notice over default on COVID vaccine royalties: BioNTech said on Monday the U.S. National Institutes of Health has sent a notice to the ...
reuters.com/business/healthcare-pharmaceuticals/biontech-gets-us-agency-notice-over-default-covid-vaccine-royalties-2024-03-25/
Sick after coronavirus vaccination? Palatinate man goes to court: A man from Pirmasens takes Biontech to court. Because he has suffered serious damage to his ...
rheinpfalz.de/lokal/pirmasens_artikel,-krank-nach-corona-impfung-pf%C3%A4lzer-zieht-vor-gericht-_arid,5628342.html
Pfizer (PFE) Plans to Sell About £2 Billion of Shares in Haleon (HLN): Pfizer Inc. plans to sell about £2 billion ($2.5 billion) of shares in Haleon Plc ...
bloomberg.com/news/articles/2024-03-18/pfizer-plans-to-sell-about-2-billion-of-shares-in-haleon
Paid articlePaid Pfizer: Attractive Valuation And A Strong Pipeline Mitigate Patent Cliff Concerns
seekingalpha.com/article/4678774-pfizer-attractive-valuation-and-a-strong-pipeline-mitigate-patent-cliff-concerns
Paid articlePaid Pfizer Is Selling a Chunk of Its Haleon Stock. It’s a $3 Billion Windfall.: The sale comes as Pfizer’s need for cash has increased. It recently closed on its $43 ...
on.barrons.com/3II1UkH
Currys Lifts Profit Outlook After Bidders Walk Away: Get briefed ahead of your morning calls with the latest UK business headlines, key data and market reaction
bloomberg.com/news/newsletters/2024-03-18/currys-lifts-profit-outlook-after-bidders-walk-away-ltwoi347
RKI doubted AstraZeneca for months: “Less perfect”, “not a sure-fire success”, “2-class vaccination”
fr.de/politik/rki-protokolle-robert-koch-institut-corona-coronavirus-impfung-astrazeneca-zr-92921607.html
If tech runs out of steam: That's why stocks from BioNTech and Co. are also exciting for investors
boerse-online.de/nachrichten/zertifikate/falls-tech-die-luft-ausgeht-darum-sind-auch-aktien-von-biontech-und-co-fuer-anleger-spannend-20353073.html
Munich: Major Biontech shareholders buy “Fünf Höfe” - for almost 800 million euros
sueddeutsche.de/muenchen/muenchen-fuenf-hoefe-verkauf-biontech-grossaktionaere-1.6472720
Biontech competitor Curevac cuts jobs in the region: High losses and a stock market crash: Curevac shows what could have happened to Biontech if the Mainz-based ...
wiesbadener-kurier.de/wirtschaft/wirtschaft-hessen-und-rheinland-pfalz/biontech-konkurrent-curevac-baut-stellen-in-der-region-ab-3428188
London's FTSE 100 opens higher on miners' boost: The UK's FTSE 100 inched higher on Monday as metal miners rose on upbeat economic data from China ...
reuters.com/markets/europe/londons-ftse-100-opens-higher-miners-boost-2024-03-18/
Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know
cnbc.com/2024/03/10/pfizer-is-betting-big-on-cancer-drugs-after-covid-decline.html
Syphilis Is Killing Babies. The U.S. Government Is Failing to Stop the Disease From Spreading.
propublica.org/article/how-federal-government-fails-stop-syphilis-babies-pregnancy
Why COVID-19 patients who could most benefit from Paxlovid still aren’t getting it
abcnews.go.com/Health/covid-19-patients-benefit-paxlovid-arent/story
COVID-19 timeline: How the deadly virus and the world's response have evolved over 4 years
abcnews.go.com/Health/covid-19-timeline-deadly-virus-worlds-response-evolved/story
What To Know About Adcetris—Pfizer’s Cancer Drug Extended Survival For Patients With Common Lymphoma
forbes.com/sites/tylerroush/2024/03/12/what-to-know-about-adcetris-pfizers-cancer-drug-extended-survival-for-patients-with-common-lymphoma/
Group suing over Pfizer diversity fellowship program loses US appeal: A U.S. appeals court on Wednesday upheld the dismissal of a lawsuit by a conservative group ...
reut.rs/48IEJ4c
CNBC Daily Open: A mixed picture on U.S. jobs growth : U.S. jobs growth continues to boom but there are also clear signs the labor market is cooling.
cnbc.com/2024/03/11/cnbc-daily-open-a-mixed-picture-on-us-jobs-growth-.html
The Age of Respiratory Syncytial Virus Prevention: Empowering Pharmacists to Optimize Disease Protection in Older Adults
medscape.org/viewarticle/999447
Pfizer: Enormous competition: The market is considered competitive.
deraktionaer.de/artikel/pharma-biotech/pfizer-enorme-konkurrenz-20354418.html
Mega potential: Will this biotech stock be as big as BioNTech and Moderna in their heyday?
boerse-online.de/nachrichten/aktien/mega-potenzial-wird-diese-biotech-aktie-so-gross-wie-biontech-und-moderna-zu-ihren-besten-zeiten--20354243.html
Pfizer (PFE) Syphilis Drug Bicillin L-A Shortage to Extend Into At Least October: The US shortage of Pfizer Inc.’s drug that’s the optimal treatment for syphilis ...
bloomberg.com/news/articles/2024-03-08/shortage-of-pfizer-syphilis-drug-will-continue-longer-than-expected
Paid articlePaid Everett Seagen plant closure will cost 119 workers their jobs in June: The 119 impacted employees were working on the setup of the Seagen manufacturing plant in ...
seattletimes.com/business/everett-seagen-plant-closure-will-cost-119-workers-their-jobs-in-june/
Publicis New York hires new chief creative officer: Joe Mongognia will lead all creative across the Publicis New York office, including the newly won Pfizer ...
adage.com/article/agency-news/publicis-new-york-hires-joe-mongognia/2550746
Paid articlePaid Next
New to NewsWall?
Sign up now to get your own personalized news!
Trending topics